Revenue - Revenue for the nine months ended July 31, 2021, was approximately $513,000 from a single license agreement, compared to no revenue in the same period in 2020[110] Expenses - Research and development expenses increased by approximately $42,000 to approximately $4,016,000 for the nine months ended July 31, 2021, from approximately $3,974,000 in the same period in 2020[114] - General and administrative expenses rose by approximately $1,408,000 to approximately $5,170,000 for the nine months ended July 31, 2021, compared to approximately $3,762,000 in the prior year[115] - Research and development expenses for CAR-T therapeutics were approximately $1,753,000, for cancer vaccines approximately $1,400,000, and for anti-viral therapeutics approximately $861,000 for the nine months ended July 31, 2021[113] Cash Flow - Cash used in operating activities was approximately $3,893,000 during the nine months ended July 31, 2021[120] - Cash provided by financing activities was approximately $31,422,000, including net proceeds of approximately $20,292,000 from a public offering of 4,285,715 shares of common stock[120] - The company raised approximately $20,292,000 through a public offering and approximately $10,834,000 through an at-the-market equity program during the nine months ended July 31, 2021[119] - The company expects existing cash and cash equivalents to be sufficient to fund activities for at least the next twelve months[119] Net Loss - The net loss attributable to noncontrolling interest was approximately $116,000 for the nine months ended July 31, 2021, compared to $57,000 in the same period in 2020[117] Interest Income - Interest income decreased by approximately $31,000 to approximately $2,000 for the nine months ended July 31, 2021, from approximately $33,000 in the prior year[116] Stock-Based Compensation - The company measures stock-based compensation costs at the grant date using the Black-Scholes pricing model and recognizes it as an expense over a service period of one to four years[127] - For stock options vesting upon achieving price targets, the company employs a Monte Carlo Simulation to estimate fair value at grant date[127] - The expected term of stock options is determined using a simplified method, which is a weighted average of the vesting term and contractual term[129] Investments - As of July 31, 2021, the company had investments in short-term, fixed rate, and highly liquid instruments, which are not considered at risk with respect to interest rate changes[131] - The rate of return on existing securities could be affected at the time of reinvestment[131]

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements.) This section presents the unaudited condensed consolidated financial statements for the three and six months ended April 30, 2021, and 2020, detailing financial position, operational results, and cash flows [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet as of April 30, 2021, reflects a substantial strengthening of the company's financial position, driven by significant increases in cash, investments, and equity from recent capital raises | Financial Metric | April 30, 2021 (Unaudited) | October 31, 2020 | | :--- | :--- | :--- | | **Cash and cash equivalents** | $27,703,435 | $6,417,061 | | **Total current assets** | $38,471,948 | $9,368,624 | | **Total assets** | $38,497,522 | $9,452,964 | | **Total current liabilities** | $1,442,871 | $1,188,591 | | **Total shareholders' equity** | $37,613,758 | $8,761,356 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) The company reported no revenue for the three months ended April 30, 2021, but recognized $512,500 in six-month revenue from a licensing agreement, with net loss and loss per share improving year-over-year | Metric | Three Months Ended April 30, 2021 | Three Months Ended April 30, 2020 | | :--- | :--- | :--- | | **Revenue** | $ - | $ - | | **Loss from operations** | $(2,437,282) | $(2,670,137) | | **Net loss attributable to common shareholders** | $(2,398,851) | $(2,640,093) | | **Net loss per share (Basic and diluted)** | $(0.08) | $(0.12) | | Metric | Six Months Ended April 30, 2021 | Six Months Ended April 30, 2020 | | :--- | :--- | :--- | | **Revenue** | $512,500 | $ - | | **Loss from operations** | $(4,670,413) | $(5,300,006) | | **Net loss attributable to common shareholders** | $(4,607,142) | $(5,232,636) | | **Net loss per share (Basic and diluted)** | $(0.17) | $(0.25) | [Condensed Consolidated Statements of Shareholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Shareholders'%20Equity) Shareholders' equity significantly increased to $37.1 million by April 30, 2021, primarily driven by approximately $31.1 million in net proceeds from public and at-the-market offerings - Completed a public offering in March 2021, selling **4,285,715 shares** and raising net proceeds of approximately **$20.3 million**[10](index=10&type=chunk)[13](index=13&type=chunk)[42](index=42&type=chunk) - Raised net proceeds of approximately **$10.8 million** from an at-the-market (ATM) offering during the six months ended April 30, 2021[14](index=14&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the six months ended April 30, 2021, cash used in operating and investing activities was significantly offset by $31.4 million provided by financing activities, resulting in a net increase of $21.3 million in cash and cash equivalents | Cash Flow Activity (Six Months Ended April 30) | 2021 | 2020 | | :--- | :--- | :--- | | **Net cash used in operating activities** | $(2,411,946) | $(3,470,654) | | **Net cash used in investing activities** | $(7,723,853) | $(285,791) | | **Net cash provided by financing activities** | $31,422,173 | $3,153,017 | | **Net increase (decrease) in cash** | $21,286,374 | $(603,428) | | **Cash and cash equivalents at end of period** | $27,703,435 | $2,888,197 | [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes detail the company's primary focus on developing oncology and infectious disease therapies and vaccines, outlining collaborations, clinical trial progress, financing activities, and segment-level financial data - The company's primary operations involve developing therapies and vaccines for oncology (CAR-T for ovarian cancer, vaccines for breast and ovarian cancer) and infectious diseases (COVID-19 therapeutics)[19](index=19&type=chunk) - An Investigational New Drug (IND) application for the CAR-T ovarian cancer therapy was submitted to the FDA in March 2021; the company is addressing an FDA information request and anticipates beginning clinical trials in **Q4 2021**[21](index=21&type=chunk) - Received FDA authorization in December 2020 to begin a Phase 1a clinical trial for a breast cancer vaccine, with the first patient expected to be treated in **July 2021**[26](index=26&type=chunk) - The company manages five reportable segments: CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, Cancer Diagnostics, and Patent Licensing; for the six months ended April 30, 2021, CAR-T Therapeutics incurred the highest operating costs excluding non-cash compensation (**$1.49 million**)[94](index=94&type=chunk)[95](index=95&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations.) Management discusses financial results, noting decreased R&D expenses due to program suspension, $513,000 in licensing revenue, and confirming sufficient liquidity for the next twelve months due to recent financing activities - For the six months ended April 30, 2021, the company recorded revenue of approximately **$513,000** from one license agreement[106](index=106&type=chunk) - Research and development expenses for the six months ended April 30, 2021 decreased by approximately **$869,000** compared to the prior year, primarily due to the suspension of the cancer diagnostics program[110](index=110&type=chunk) - The company believes its existing cash, cash equivalents, and short-term investments are sufficient to fund activities for at least the next twelve months, supported by approximately **$31.1 million** in net proceeds from a public offering and an at-the-market program in H1 2021[116](index=116&type=chunk) - Management identifies Revenue Recognition and Stock-Based Compensation as its most critical accounting policies, which require significant judgments and estimates[120](index=120&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=29&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk.) The company's market risk is limited to interest rate risk on its short-term, fixed-rate, and highly liquid investments, which could affect future returns upon reinvestment - The company's investments consist of short-term, fixed-rate, and highly liquid instruments, which are subject to interest rate risk that could affect returns upon reinvestment[128](index=128&type=chunk) [Controls and Procedures](index=29&type=section&id=Item%204.%20Controls%20and%20Procedures.) Management concluded that disclosure controls and procedures were effective as of April 30, 2021, with no material changes to internal control over financial reporting during the quarter - Management concluded that disclosure controls and procedures are effective as of the end of the reporting period[129](index=129&type=chunk) - No material changes were made to the company's internal control over financial reporting during the second quarter of fiscal year 2021[129](index=129&type=chunk) [PART II. OTHER INFORMATION](index=30&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=30&type=section&id=Item%201.%20Legal%20Proceedings.) The company is not involved in any litigation or other legal proceedings that would have a material adverse effect on its financial condition or results of operations - The company is not involved in any material litigation or legal proceedings[131](index=131&type=chunk) [Risk Factors](index=30&type=section&id=Item%201A.%20Risk%20Factors.) There have been no material changes to the company's risk factors from those disclosed in its Annual Report on Form 10-K for the fiscal year ended October 31, 2020 - No material changes in risk factors have occurred since the fiscal year 2020 Form 10-K filing[132](index=132&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=30&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds.) The company reported no unregistered sales of equity securities during the period - None[132](index=132&type=chunk) [Exhibits](index=30&type=section&id=Item%206.%20Exhibits.) This section lists the exhibits filed with the Form 10-Q, including an assignment agreement, an amendment to a collaboration agreement, and CEO/CFO certifications - Filed exhibits include an Assignment Agreement with OntoChem GmbH and MolGenie GmbH, and CEO/CFO certifications pursuant to the Sarbanes-Oxley Act[133](index=133&type=chunk) [Signatures](index=31&type=section&id=SIGNATURES) - The report was signed on **June 10, 2021**, by **Dr. Amit Kumar**, Chairman, President and CEO, and **Michael J. Catelani**, COO and CFO[135](index=135&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2020 Commission file number 001-37492 ANIXA BIOSCIENCES, INC. | --- | --- | |----------------------------------------------------------------------------|----------------------------------------------| | (Exact name of registrant as \nDelaware | specified in its charter) \n11-2622630 | | (State or oth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2020 Commission file number 0-11254 | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------| | Delaware ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2020 Commission file number 0-11254 ANIXA BIOSCIENCES, INC. | --- | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|--------------------------- ...

Financial Performance - In fiscal year 2019, the company recorded revenue of $250,000 from one license agreement, a decrease of approximately 77.5% compared to $1,113,000 from two license agreements in fiscal year 2018[127] - Inventor royalties and contingent legal fees related to patent assertion activities decreased by approximately $602,000 to approximately $166,000 in fiscal year 2019, down from approximately $768,000 in fiscal year 2018[128] - Research and development expenses decreased by approximately $1,340,000 to approximately $5,473,000 in fiscal year 2019, compared to approximately $6,813,000 in fiscal year 2018[130] - General and administrative expenses decreased by approximately $1,249,000 to approximately $5,663,000 in fiscal year 2019, down from approximately $6,912,000 in fiscal year 2018[131] - Interest income increased to approximately $71,000 in fiscal year 2019, compared to approximately $46,000 in fiscal year 2018, due to an increase in funds available for short-term investments[134] - Cash used in operating activities was approximately $4,773,000 during the year ended October 31, 2019[138] - Cash provided by financing activities was approximately $5,734,000, resulting from the sale of 1,363,872 shares of common stock in an at-the-market equity offering[138] - The company raised approximately $5,527,000 through an at-the-market equity offering during fiscal year 2019[136] - The impairment in carrying amount of patent assets was approximately $419,000 in fiscal year 2019, compared to approximately $583,000 in fiscal year 2018[133] - The net loss attributable to noncontrolling interest decreased by approximately $75,000 to approximately $172,000 in fiscal year 2019, from approximately $247,000 in fiscal year 2018[135] Corporate Governance - Management assessed the effectiveness of internal control over financial reporting as of October 31, 2019, concluding it was effective[148] - No changes in internal control over financial reporting during Q4 2019 that materially affected the company's controls[149] - The company entered into a settlement regarding a shareholder derivative complaint, agreeing to changes in corporate governance policies[164] - The Nominating Committee is responsible for identifying qualified individuals for board membership, composed exclusively of independent directors[168] - The company has established a formal code of ethics applicable to its principal executive and financial officers, available upon request[166] - The Audit Committee is composed of independent directors, with David Cavalier serving as the Chairman and qualifying as an Audit Committee financial expert[173] - The company evaluated the effectiveness of its disclosure controls and procedures, concluding they were effective as of the end of fiscal year 2019[147] - The company has no significant employees other than its executive management team[160] - There are no family relationships among the directors or executive officers of the company[161] - The Company will hold an advisory vote on named executive officer compensation every year until at least the Annual Meeting of Shareholders in 2025[151] - The 2020 Annual Meeting of Shareholders is scheduled for July 15, 2020, with a deadline for shareholder proposals set for May 11, 2020[151] Leadership and Board Composition - Dr. Amit Kumar has served as CEO since July 2017 and has extensive experience in technology-driven startups and biotechnology[153] - Lewis H. Titterton has been a director since 2017 and has over 40 years of experience in the technology industry[155] - David Cavalier, a director since 2018, has over 20 years of experience in biotechnology and was instrumental in securing a $118 million contract from the U.S. Government[157] - Emily Gottschalk, a director since 2019, has developed over 150 million CDs/DVDs for the U.S. retail market since 1997[157] - Dr. John Monahan has served on the Board since 2016 and has over 50 publications in scientific literature[157] - The Chief Operating Officer and Chief Financial Officer, Michael J. Catelani, has over 30 years of experience in finance and operations, previously managing a $150 million drug development collaboration with Pfizer[159] - The Company has a diverse board with members having backgrounds in biotechnology, finance, and healthcare, enhancing its strategic development capabilities[153] - The Board of Directors includes members with extensive experience in public companies and biotechnology, contributing to informed decision-making[159] - Michael J. Catelani has been the Chief Operating Officer since July 2017 and Chief Financial Officer since November 2016, with over 30 years of experience in finance and operations[159] - David Cavalier, a director since September 2018, was instrumental in securing a $118 million advanced research and development contract from the U.S. Government in 2011[157] Legal and Compliance Matters - A putative shareholder derivative complaint was filed alleging breach of fiduciary duty and unjust enrichment against certain current and former officers and directors[164] - The company entered into a settlement on August 21, 2019, agreeing to changes in corporate governance policies and to reprice certain stock options to $0.67[164] - All claims in the derivative action have been dismissed, with individual defendants denying any wrongdoing[164] - The company believes all required Section 16(a) reports were made on a timely basis during fiscal year 2019[165] - The Nominating Committee considers candidates' integrity, experience, and ability to contribute to the board's diversity[168] - The company has not engaged any third party to assist in identifying or evaluating director nominees[170]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2019 Commission file number 0-11254 ANIXA BIOSCIENCES, INC. | --- | --- | --- | |-------------------------------------------------|--------------------------------------------------------|-----------------------------| | | (Exact name of registrant as specified in its charter) | | | Delaware (State or ...